Lilly's gastric cancer drug meets late-stage goal
Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.
The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.
The study, named REGARD, also improved survival without the cancer worsening.
- Scots spurn independence, vote to stay in the United Kingdom |
- Eight bodies found after attack on Guinea Ebola education team
- Scots independence polls close, UK's future in the balance |
- Alibaba IPO prices at top of range, raising $21.8 billion |
- Two adults, six children dead in Florida shooting: report